BACKGROUND: The intracellular and plasma concentrations of HIV protease inhibitors (HPIs) vary widely in vivo. It is unclear whether there is a concentration-dependent effect of HPIs such that at increasing concentration they may either block their own efflux (leading to 'autoboosting') or influx (leading to saturability/decreased intracellular accumulation). METHOD: The effects of various concentrations (0-30 microM) of lopinavir, saquinavir, ritonavir and atazanavir on the accumulation of [(14)C]lopinavir, [(3)H]saquinavir, [(3)H]ritonavir and [(3)H]atazanavir, respectively, were investigated in CEM(parental), CEM(VBL) [P-glycoprotein (ABCB1) overexpressing], CEM(E1000) (MRP1 overexpressing) and in peripheral blood mononuclear cells (PBMCs). We also investigated the effects of inhibitors of ABCB1/ABCG2 (tariquidar), ABCC (MK571) and ABCC1/2 (frusemide), singly and in combination with HPIs, on cellular accumulation. RESULTS: In all the cell lines, with increasing concentration of lopinavir, saquinavir and ritonavir, there was a significant increase in the cellular accumulation of [(14)C]lopinavir, [(3)H]saquinavir and [(3)H]ritonavir. Tariquidar, MK571 and frusemide (alone and in combination with lopinavir, saquinavir and ritonavir) significantly increased the accumulation of [(14)C]lopinavir, [(3)H]saquinavir and [(3)H]ritonavir. Ritonavir (alone or in combination with tariquidar) decreased the intracellular accumulation of [(3)H]ritonavir in PBMCs. Atazanavir decreased the accumulation of [(3)H]atazanavir in a concentration-dependent manner in all of the cells tested. CONCLUSIONS: There are complex and variable drug-specific rather than class-specific effects of the HPIs on their own accumulation.
BACKGROUND: The intracellular and plasma concentrations of HIV protease inhibitors (HPIs) vary widely in vivo. It is unclear whether there is a concentration-dependent effect of HPIs such that at increasing concentration they may either block their own efflux (leading to 'autoboosting') or influx (leading to saturability/decreased intracellular accumulation). METHOD: The effects of various concentrations (0-30 microM) of lopinavir, saquinavir, ritonavir and atazanavir on the accumulation of [(14)C]lopinavir, [(3)H]saquinavir, [(3)H]ritonavir and [(3)H]atazanavir, respectively, were investigated in CEM(parental), CEM(VBL) [P-glycoprotein (ABCB1) overexpressing], CEM(E1000) (MRP1 overexpressing) and in peripheral blood mononuclear cells (PBMCs). We also investigated the effects of inhibitors of ABCB1/ABCG2 (tariquidar), ABCC (MK571) and ABCC1/2 (frusemide), singly and in combination with HPIs, on cellular accumulation. RESULTS: In all the cell lines, with increasing concentration of lopinavir, saquinavir and ritonavir, there was a significant increase in the cellular accumulation of [(14)C]lopinavir, [(3)H]saquinavir and [(3)H]ritonavir. Tariquidar, MK571 and frusemide (alone and in combination with lopinavir, saquinavir and ritonavir) significantly increased the accumulation of [(14)C]lopinavir, [(3)H]saquinavir and [(3)H]ritonavir. Ritonavir (alone or in combination with tariquidar) decreased the intracellular accumulation of [(3)H]ritonavir in PBMCs. Atazanavir decreased the accumulation of [(3)H]atazanavir in a concentration-dependent manner in all of the cells tested. CONCLUSIONS: There are complex and variable drug-specific rather than class-specific effects of the HPIs on their own accumulation.
Authors: W Cavert; D W Notermans; K Staskus; S W Wietgrefe; M Zupancic; K Gebhard; K Henry; Z Q Zhang; R Mills; H McDade; C M Schuwirth; J Goudsmit; S A Danner; A T Haase Journal: Science Date: 1997-05-09 Impact factor: 47.728
Authors: J Ford; E R Meaden; P G Hoggard; M Dalton; P Newton; I Williams; S H Khoo; D J Back Journal: J Antimicrob Chemother Date: 2003-08-13 Impact factor: 5.790
Authors: Loren M Kinman; Julie M Worlein; Jennifer Leigh; Helle Bielefeldt-Ohmann; David M Anderson; Shiu-Lok Hu; William R Morton; Bradley D Anderson; Rodney J Y Ho Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: Ralf Winzer; P Langmann; M Zilly; F Tollmann; J Schubert; H Klinker; B Weissbrich Journal: Eur J Med Res Date: 2003-12-09 Impact factor: 2.175
Authors: Loren Kinman; Scott J Brodie; Che Chung Tsai; Tot Bui; Kay Larsen; Ann Schmidt; David Anderson; William R Morton; Shiu-Lok Hu; Rodney J Y Ho Journal: J Acquir Immune Defic Syndr Date: 2003-12-01 Impact factor: 3.731
Authors: Martina Hennessy; Susan Clarke; J Paul Spiers; Dermot Kelleher; Fiona Mulcahy; Patrick Hoggard; David Back; Michael Barry Journal: Antivir Ther Date: 2004-02
Authors: Becky Chandler; Lisa Almond; Jennifer Ford; Andrew Owen; Patrick Hoggard; Saye Khoo; David Back Journal: J Acquir Immune Defic Syndr Date: 2003-08-15 Impact factor: 3.731